Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma

Cancer of Head and Neck Clinical Trial

— TPFmORL  

Official title:

A Phase II Randomized Trial, Non Comparative, Evaluating Chemotherapy Associated Cisplatin, 5-fluorouracil and Docetaxel at Adapted Doses in Patients With Locally Advanced Squamous Cell Carcinoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04356170
• Other study ID #: GORTEC 2019-01
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 4, 2021
• Est. completion date: July 2025

Study information

• Verified date: March 2024
• Source: Groupe Oncologie Radiotherapie Tete et Cou
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacity of the combination of cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without toxicity

.

Description:

After explaining the treatment modalities, having read and explained the information letter to them, patients who have signed the consent to participate in the trial and who meet the inclusion criteria will be enrolled and randomized in the trial .

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 105
• Est. completion date: July 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

1. Histologically proven squamous cell carcinoma of the head and neck from one or more of the following primary sites: oral cavity, oropharynx, hypopharynx or larynx, lymphadenopathy without front door

2. Inoperable tumor or tumor whose surgery would be multilating.

The non-operability criteria are:

• Technically impossible resection: fixation / invasion of the tumor at the base of the skull or at the cervical vertebrae, nasopharynx involved, lymph nodes

• Medical selection based on low surgical curability. This category includes all T3-T4 and all N2-N3 (AJCC 8th edition, June 2018)

• Medical selection based on an organ preservation strategy

3. Patient not previously treated for ORL cancer

4. Age > 18 and < 75 years

5. PS 0 or 1 according to WHO

6. At least one lesion measurable according to the RECIST 1.1 criteria

7. Patient who can receive TPF according to the following criteria:

• Adequate hematological function: neutrophils ³ 1.5 x 109 / l, platelets *100 x 109 / l, hemoglobin 10 g / dl (or 6.2 mmol / l)

• Adequate renal function: calculated creatinine clearance (Cockroft & Gault) or measured ³ 60 ml / min.

• Adequate liver function: normal total bilirubin; ASAT and ALAT less than or equal to 1.5 ´ LNS; PAL less than or equal to 2.5 X LNS

• Grade <2 peripheral neuropathy according to NCI CTCAE v5.0

• No clinical impairment of hearing function

• For patients aged 71 to 74, PS at 0 and considered non-geriatrically fragile (G8 questionnaire and multidimensional assessments proposed by the GERICO group (ADL, MMSE, GDS scale, nutrition, motor skills and balance, geographic and personal situation and assessments) thymic))

8. Estimated life expectancy greater than or equal to 3 months

9. Weight loss of less than 10% during the 3 months before randomization

10. Patient understanding French and able to complete quality of life questionnaires

11. Patient having given written consent before any specific protocol procedure

12. Affiliation to a social security scheme or beneficiary of such a scheme

13. Women of childbearing potential and sexually active men agreeing to use effective contraceptive methods for the duration of treatment and at least 6 months after the last administration of study treatments

14. Patient agrees not to donate sperm for the duration of the treatment and at least 6 months after the last administration of the study treatments

15. Absence of deficiency in dihydropyrimidine dehydrogenase activity determined by uracilemia assay (Uracilemia < 16 ng/mL)

Exclusion Criteria:

1. Cancers of the nasopharynx, sinuses or nasal cavities, and any histology other than squamous cell carcinoma

2. Vaccination against recent or planned yellow fever

3. Known deficiency in dihydropyrimidine dehydrogenase (DPD) or determined by the determination of uricemia.

4. History of other cancer except in situ cervical cancer or controlled basal cell carcinoma. Patients in remission from cancer treated more than 3 years ago are eligible. Patients treated by surgery alone for ORL cancer in the previous 3 years are eligible.

5. Previous treatment of an ORL cancer by chemotherapy or radiotherapy. Patients treated by surgery alone for ORL cancer in the previous 3 years are eligible).

6. Presence of distant metastasis.

7. Participation in a therapeutic trial in the 30 days preceding randomization

8. Concomitant anticancer treatment

9. Patient under chronic treatment (3 months) with corticosteroid whose daily dosage is 10 mg / day of methylprednisolone or equivalent

10. Other existing serious medical pathologies (non-exhaustive list):

• Uncontrolled cardiac pathology despite adequate treatment

• Myocardial infarction in the 6 months preceding randomization

• Neurological or psychiatric history such as dementia, convulsions

• Active infection

• Significant gastrointestinal abnormalities, including those that require parenteral nutrition, active peptic ulcer, and history of surgeries affecting absorption

• Obstructive pulmonary disease requiring hospitalization in the year preceding randomization

• Uncontrolled type II diabetes or other corticosteroid contraindications.

• Moderate or severe eczema

11. Known hypersensitivity to docetaxel, cisplatin 5FU or one of their excipients.

12. Intended concomitant use of phenytoin, carbamazepine, barbiturates or rifampicin

13. Presence, upon selection, of psychological, family, social or geographic factors likely to influence the patient's compliance with the study and monitoring protocol.

14. Pregnant or lactating woman

15. Patient (male or female) of reproductive age who is unable or unwilling to take adequate contraceptive measures during treatment and up to 6 months after the last treatment is administered.

16. Persons deprived of their liberty, under guardianship or curatorship

Related Conditions & MeSH terms

• Cancer of Head and Neck
• Head and Neck Neoplasms

Intervention

Drug:
• Docetaxel
Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
• Cisplatin
cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
• Fluoro Uracil
750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)

Locations

Country	Name	City	State
France	Centre Leon Berard	Lyon

Sponsors (2)

Lead Sponsor	Collaborator
Groupe Oncologie Radiotherapie Tete et Cou	Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Overall survival	The time from date of randomization to date of death due to any cause	3 months after the end of treatment
Other	Progression free survival	The time from date randomization to date of first evidence of progression	3 months after the end of treatment
Other	incidence of local and/or locorégional failure		3 months after the end of treatment
Other	Laryngeal preservation		3 months after the end of treatment
Other	incidence of distant metastatic failure	The time from the date of randomization and the date of first evidence of metastatic progression, or the date of death, whatever the cause	3 months after the end of treatment
Other	Toxicities of complementary treatment to induction tretatment	Rate of patients who received the whole of complementary treatment	3 months after the end of treatment
Other	QLQ-C30 questionnaires	These questionnaires assess the impact of the desease and treatment on tthe patient's life	8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment
Other	QLQ-H&N35 questionnaires	These questionnaires assess the impact of the desease and treatment on tthe patient's life	8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment
Primary	Efficacity of combination of TPFm	Success rate of patients at 8 weeks	8 weeks after the end of treatment